Cargando…

Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature

Oral systemic therapies are important treatment options for patients with moderate-to-severe psoriasis, either as monotherapy or in therapy-recalcitrant cases as combination therapy with phototherapy, other oral systemics or biologics. Long-term treatment is needed to maintain sufficient disease con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balak, Deepak M. W., Gerdes, Sascha, Parodi, Aurora, Salgado-Boquete, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367959/ https://www.ncbi.nlm.nih.gov/pubmed/32529393 http://dx.doi.org/10.1007/s13555-020-00409-4

Ejemplares similares

Fumaric acid esters in the management of psoriasis
por: Balak, Deepak MW
Publicado: (2015)

Drug-induced psoriasis: clinical perspectives
por: Balak, Deepak MW, et al.
Publicado: (2017)

A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis?
por: Salgado-Boquete, Laura, et al.
Publicado: (2021)

The long-term efficacy and safety of new biological therapies for psoriasis
por: Papp, Kim A.
Publicado: (2006)

Obesity — A Risk Factor for Psoriasis and COVID-19()
por: Llamas-Velasco, M., et al.
Publicado: (2021)

“De Novo” Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature
por: Trave, Ilaria, et al.
Publicado: (2023)

Obesidad: factor de riesgo para psoriasis y COVID-19
por: Llamas-Velasco, M., et al.
Publicado: (2021)

Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies
por: Balak, Deepak M W, et al.
Publicado: (2021)

Cutaneous adverse events associated with long-term immunomodulating therapy in multiple sclerosis
por: Balak, Deepak MW, et al.
Publicado: (2011)

Anti‐interleukin‐17A for pityriasis rubra pilaris: catching the psoriasis biologic wave
por: Balak, Deepak M.W., et al.
Publicado: (2022)

Psoriasis, Vitiligo, and Biologic Therapy: Case Report and Narrative Review
por: Burlando, Martina, et al.
Publicado: (2021)

Psoriasis flares after COVID-19 vaccination: adherence to biologic therapy reduces psoriasis exacerbations: a case-control study
por: Burlando, Martina, et al.
Publicado: (2023)

Switch of psoriasis therapy from a fumaric acid ester mixture to dimethyl fumarate monotherapy: Results of a prospective study
por: Falkvoll, Sandra, et al.
Publicado: (2019)

Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
por: Kivelevitch, Dario, et al.
Publicado: (2014)

Long-term safety of etanercept in psoriasis: Retrospective study focused on infections
por: Orsini, Diego, et al.
Publicado: (2016)

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
por: Al-Janabi, A, et al.
Publicado: (2022)

Guselkumab‐associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature
por: Burlando, Martina, et al.
Publicado: (2021)

Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients
por: Burlando, Martina, et al.
Publicado: (2022)

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
por: Leonardi, Craig, et al.
Publicado: (2020)

Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)
por: Daudén, Esteban, et al.
Publicado: (2022)

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management [Corrigendum]
Publicado: (2022)

Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Long-Term Usage of Oral Glucocorticoids Leading to Adrenal Insufficiency: A Comprehensive Review of the Literature
por: Monge Chacón, Ana G, et al.
Publicado: (2023)

The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients
por: Mrowietz, Ulrich, et al.
Publicado: (2006)

Long‐term safety of brodalumab in Japanese patients with plaque psoriasis: An open‐label extension study
por: Yamaguchi, Yukie, et al.
Publicado: (2020)

Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature
por: Moore, Angela Y, et al.
Publicado: (2010)

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
por: Burlando, Martina, et al.
Publicado: (2021)

Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2023)

Oral Vitamin D Therapy in Patients with Psoriasis
por: Stanescu, Ana Maria Alexandra, et al.
Publicado: (2021)

Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review
por: Vincken, Nanette L A, et al.
Publicado: (2022)

Handlungsempfehlungen zur individuellen Risikoermittlung von Komorbidität bei erwachsenen Patienten mit Psoriasis
por: Wohlrab, Johannes, et al.
Publicado: (2023)

Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study)
por: Narcisi, Alessandra, et al.
Publicado: (2020)

A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis
por: Haque, Emily K., et al.
Publicado: (2020)

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis
por: Gordon, K.B., et al.
Publicado: (2021)

Dynamic QuantiFERON Response in Psoriasis Patients Taking Long-Term Biologic Therapy
por: Drago, Lorenzo, et al.
Publicado: (2013)

Spotlight on Topical Long-Term Management of Plaque Psoriasis
por: Carrascosa, Jose Manuel, et al.
Publicado: (2020)

Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study
por: Pirro, Federico, et al.
Publicado: (2021)

Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study
por: Balak, Deepak MW, et al.
Publicado: (2013)

Severe Generalized Pustular Psoriasis Successfully Treated with Ixekizumab: A Case Report
por: Burlando, Martina, et al.
Publicado: (2022)

Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report
por: Burlando, Martina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mub8ims3daephnddn4pm9ugbnf